NovoCure Ltd (FRA:038)
€ 16.225 -0.425 (-2.55%) Market Cap: 1.75 Bil Enterprise Value: 1.48 Bil PE Ratio: 0 PB Ratio: 5.23 GF Score: 69/100

Novocure Ltd at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 02:30PM GMT
Release Date Price: €76.7 (+6.60%)
Jason M. Bednar
Piper Sandler & Co., Research Division - VP & Senior Research Analyst

All right. Good morning. Why don't we get started here? I'm Jason Bednar. I cover med tech here at Piper. Next fireside chat is with NovoCure. Very happy to have with us the Executive Chairman, Bill Doyle; and CFO, Ashley Cordova. Thanks a lot both of you for being here today.

William F. Doyle
NovoCure Limited - Executive Chairman

Our pleasure.

Questions & Answers

Jason M. Bednar
Piper Sandler & Co., Research Division - VP & Senior Research Analyst

So why don't we start with maybe some of the recent updates, I do want to get into -- it feels like topic du jour for the past 18 months, LUNAR. But why don't we first talk about, you had some recent updates on Canada. You recently had approval for Optune in Canada. And congratulations on that. Nice geographic expansion, really to go along with some of your other efforts in Europe. Is the plan to wait to commercialize in Canada until you have reimbursement in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot